PROGilead Sciences Inc
stock147.92
-2.51 (-1.67%)
Price as of 14 Oct, 02:30 · Rate limit reached. Please try again in a minute.
Good Money Guide Pro Score
Attractive
Attractive investment profile
Technical Analysis
Short-Term Outlook
Neutral
2 bull · 2 bear · 1 neutral
Medium-Term Outlook
Bullish
4 bull · 0 bear · 0 neutral
Price above 50-day MA
Price above 200-day MA
Price above 12-day EMA
Price above 26-day EMA
Neutral momentum zone
MACD above signal line
Overbought — potential reversal down
Price near upper band — potential reversal
Volatility measure — informational only
Market Statistics
Day Change
-2.51
Market Cap
166718013000
Exchange
NASDAQ
Sector
Health Care
Fundamentals
Rate limit reached. Please try again in a minute.
Analyst Forecast
Rate limit reached. Please try again in a minute.
Fundamental Analysis
Unable to load fundamental data
Learn about Gilead Sciences Inc
What is Gilead Sciences Inc?
Gilead Sciences Inc. is a biopharmaceutical company that specializes in researching and developing innovative medicines to treat life-threatening diseases. They are widely recognized for their major breakthroughs in antiviral therapies, particularly in the areas of HIV, hepatitis, and oncology. The company operates by discovering new treatments and distributing them globally to improve patient health outcomes.
Is Gilead Sciences Inc a good investment?
Gilead is often noted for its strong dividend yield and robust cash flow from its existing drug portfolio, though investors must consider the risks of patent expirations and high research costs for new products. Future growth depends heavily on their ability to successfully bring new oncology and inflammatory treatments to market. Please remember that this information is for educational purposes only and does not constitute financial advice.
How do you invest in Gilead Sciences Inc?
You can invest in Gilead Sciences by purchasing shares directly through a regulated stockbroker or investment app that provides access to the NASDAQ exchange. Additionally, you may gain exposure to the company through broad healthcare-focused exchange-traded funds (ETFs) or mutual funds that hold GILD in their portfolios. Ensure you choose a reputable platform that fits your long-term financial strategy.
Educational content generated by AI — not financial advice.
Time & Sales
No trades yet.
News & Sentiment
Rate limit reached. Please try again in a minute.
Community Discussion
No posts yet for GILD — be the first to start the discussion.
Point & Figure Analysis
Famous Investors Holding GILD
Jim Simons
2.22M sh · 0.4% of portfolio
$280.14M
NEW
Ken Griffin
2.15M sh · 0.0% of portfolio
$271.67M
NEW
Ken Griffin
1.33M sh · 0.0% of portfolio
$168.04M
NEW
Ken Griffin
1.08M sh · 0.0% of portfolio
$136.33M
NEW
Ken Griffin
1.02M sh · 0.0% of portfolio
$128.42M
NEW
Ray Dalio
290.9K sh · 0.2% of portfolio
$36.75M
NEW
Ken Fisher
18.9K sh · 0.0% of portfolio
$2.39M
NEW
Source: SEC Form 13F, reporting period 30 Jun 2026. 45-day lag applies.